A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Ubrogepant (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Adverse reactions
- Sponsors Allergan
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2016 Status changed from not yet recruiting to recruiting.
- 31 Aug 2016 Planned initiation date changed from 1 Aug 2016 to 1 Sep 2016.